San Diego, CA – October 14, 2015 – Sevion Therapeutics, Inc. (“Sevion” or the “Company”) (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal year ended June 30, 2015 (“Fiscal 2015”) and also provided an overview of corporate accomplishments and plans.
Fiscal Fourth Quarter 2015 and Recent Highlights
- Completed Private Placement Financing for Gross Proceeds of Approximately $6.5 Million. On July 27, 2015, the Company conducted the final closing of a private placement with certain accredited investors whereby the Company sold units consisting of either (i) shares of common stock, or (ii) shares of Series C convertible preferred stock, and warrants for aggregate gross proceeds of approximately $6.5 million.
- Presented Antibody Discovery Platform at International Conference. In September, the Company gave an oral presentation at the Discovery on Target Drug Discovery conference in Boston, MA on the Company’s unique discovery platform for monoclonal antibodies against challenging multipass membrane protein targets.
Fiscal 2015 Financial Results
The Company reported revenue for Fiscal 2015 of $75,000 representing amortization of deferred revenue for a collaboration and option agreement. Revenue for the fiscal year ended June 30, 2014 (“Fiscal 2014”) was $100,000 consisting of a milestone payment in connection with an agricultural license agreement.
Research and development expenses for the Fiscal 2015 were $4.6 million compared to $3.3 million for Fiscal 2014. The increase was primarily due to an increase in payroll, rent and research supplies resulting from the acquisition of Fabrus, Inc. (“Fabrus”) in May 2014. The increase was partially offset by:
- the completion of the Company’s clinical trial in September 2014;
- the termination of its research agreement with the University of Waterloo in December 2014; and
- a gain on the forgiveness of debt from settlements of accounts payable with certain vendors.
General and administrative expenses were $3.2 million for the Fiscal 2015 compared to $3.7 million for Fiscal 2014. The decrease was primarily due to:
- a decrease in stock-based compensation;
- a decrease in investor relations fees due to a change in the investor relations program in June 2014; and
- a decrease in depreciation and amortization due to write off of patents being amortized.
This decrease was partially offset by an increase in payroll and professional fees due to the acquisition of Fabrus, severance payments to terminated employees and legal fees as a result of closing the New Jersey office and an increase in Delaware franchise taxes.
The loss applicable to common shares for the Fiscal 2015 was $18.9 million, or $(1.31) per share, compared with a loss applicable to common shares for Fiscal 2014 of $13.9 million, or $(2.53) per share. This decrease in the loss applicable to common shares was primarily the result of a decrease in dividends on preferred stock, which was partially offset by impairment of goodwill impairment and write-off of patents.
As of June 30, 2015, the Company had cash and cash equivalents of $3.3 million, compared to cash and cash equivalents of $6.1 million as of June 30, 2014. With the net proceeds from the private placement closing that occurred on July 27, 2015, the Company believes that it has sufficient funds to maintain operations through June 2016.
About Sevion Therapeutics
Sevion Therapeutics is a biopharmaceutical company building and developing a portfolio of innovative therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company’s product candidates are derived from multiple key proprietary technology platforms: cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. Sevion has leveraged these technologies to build a pipeline of innovative product candidates. For more information, please visit seviontherapeutics.com.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company’s ability to continue as a going concern; the ability of the Company to consummate additional financings; the development of the Company’s gene and antibody technology; the approval of the Company’s patent applications; the current uncertainty in the patent landscape surrounding small inhibitory RNA and the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company’s common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
James Schmidt, CFO